Login Join for free
Popular Searches
Popular news More >
SEARCHING....
no results found
  • Real Time Chart Real Time Chart
  • Stock Profile Stock Profile

  • Financials As Reported

    • accession Number 0000874015-23-000136
    • accounts Payable Current 10,499,000
    • accumulated Other Comprehensive Income Loss Net Of Tax --48,983,000
    • allocated Share Based Compensation Expense 26,948,000
    • amendment Flag false
    • assets 2,885,221,000
    • assets Current 2,542,619,000
    • cash And Cash Equivalents At Carrying Value 309,031,000
    • cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 309,031,000
    • cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 32,559,000
    • cik 874,015
    • city Area Code 760
    • common Stock Par Or Stated Value Per Share 0.001
    • common Stock Shares Authorized 300,000,000
    • common Stock Shares Issued 143,022,539
    • common Stock Shares Outstanding 143,022,539
    • comprehensive Income Net Of Tax --115,826,000
    • contract With Customer Liability Current 92,335,000
    • cost Of Goods And Services Sold 1,343,000
    • current Fiscal Year End Date --12-31
    • date Filed 2023-05-03
    • depreciation 2,604,000
    • document Fiscal Period Focus Q1
    • document Fiscal Year Focus 2,023
    • document Period End Date 2023-03-31
    • document Transition Report false
    • document Type 10-Q
    • earnings Per Share Basic -0.87
    • earnings Per Share Diluted -0.87
    • entity Address Address Line 1 2855 Gazelle Court
    • entity Address City Or Town Carlsbad
    • entity Address Postal Zip Code 92,010
    • entity Address State Or Province CA
    • entity Central Index Key 874,015
    • entity Current Reporting Status Yes
    • entity Emerging Growth Company false
    • entity File Number 000-19125
    • entity Filer Category Large Accelerated Filer
    • entity Incorporation State Country Code DE
    • entity Interactive Data Current Yes
    • entity Name IONIS PHARMACEUTICALS INC
    • entity Registrant Name Ionis Pharmaceuticals, Inc.
    • entity Shell Company false
    • entity Small Business false
    • entity Tax Identification Number 33-0336973
    • income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest --112,943,000
    • income Tax Expense Benefit 11,400,000
    • increase Decrease In Accounts Payable --10,295,000
    • increase Decrease In Contract With Customer Liability --13,037,000
    • increase Decrease In Inventories 167,000
    • increase Decrease In Other Operating Assets --5,312,000
    • interest Expense 1,608,000
    • interest Paid Net 89,000
    • inventory Net 22,200,000
    • irs Number 330,336,973
    • liabilities 2,398,651,000
    • liabilities And Stockholders Equity 2,885,221,000
    • liabilities Current 259,221,000
    • local Phone Number 931-9200
    • net Cash Provided By Used In Financing Activities 492,087,000
    • net Cash Provided By Used In Investing Activities --325,640,000
    • net Cash Provided By Used In Operating Activities --133,992,000
    • net Income Loss --124,323,000
    • operating Income Loss --114,148,000
    • operating Lease Liability Noncurrent 177,000,000
    • operating Lease Right Of Use Asset 179,148,000
    • other Assets Current 159,724,000
    • other Assets Noncurrent 78,296,000
    • other Liabilities Current 8,239,000
    • other Liabilities Noncurrent 7,487,000
    • other Nonoperating Income Expense 230,000
    • payments Related To Tax Withholding For Share Based Compensation 0
    • payments To Acquire Available For Sale Securities Debt 688,278,000
    • payments To Acquire Property Plant And Equipment 10,472,000
    • period End 1,680,220,800,000
    • period Start 1,672,531,200,000
    • property Plant And Equipment Net 85,158,000
    • report Link https://www.sec.gov/Archives/edgar/data/874015/000087401523000136/form10q_htm.xml
    • retained Earnings Accumulated Deficit --1,553,948,000
    • revenue From Contract With Customer Excluding Assessed Tax 130,524,000
    • selling General And Administrative Expense 45,516,000
    • share Based Compensation 26,948,000
    • stockholders Equity 486,570,000
    • trading Symbol IONS
    • update 1970-01-01
    • weighted Average Number Of Diluted Shares Outstanding 142,735,000
    • weighted Average Number Of Shares Outstanding Basic 142,735,000
    • id REPORTED_FINANCIALS
    • key IONS
    • subkey 10-Q
    • date 2023-05-03
    • updated 2023-05-04
  • Symbol Info Symbol Info
  • Symbol Over View Symbol Over View
  • Technical Analysis Technical Analysis

IONS stock fundamentals - financials as reported

Financials As Reported

  • accession Number 0000874015-23-000136
  • accounts Payable Current 10,499,000
  • accumulated Other Comprehensive Income Loss Net Of Tax --48,983,000
  • allocated Share Based Compensation Expense 26,948,000
  • amendment Flag false
  • assets 2,885,221,000
  • assets Current 2,542,619,000
  • cash And Cash Equivalents At Carrying Value 309,031,000
  • cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 309,031,000
  • cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 32,559,000
  • cik 874,015
  • city Area Code 760
  • common Stock Par Or Stated Value Per Share 0.001
  • common Stock Shares Authorized 300,000,000
  • common Stock Shares Issued 143,022,539
  • common Stock Shares Outstanding 143,022,539
  • comprehensive Income Net Of Tax --115,826,000
  • contract With Customer Liability Current 92,335,000
  • cost Of Goods And Services Sold 1,343,000
  • current Fiscal Year End Date --12-31
  • date Filed 2023-05-03
  • depreciation 2,604,000
  • document Fiscal Period Focus Q1
  • document Fiscal Year Focus 2,023
  • document Period End Date 2023-03-31
  • document Transition Report false
  • document Type 10-Q
  • earnings Per Share Basic -0.87
  • earnings Per Share Diluted -0.87
  • entity Address Address Line 1 2855 Gazelle Court
  • entity Address City Or Town Carlsbad
  • entity Address Postal Zip Code 92,010
  • entity Address State Or Province CA
  • entity Central Index Key 874,015
  • entity Current Reporting Status Yes
  • entity Emerging Growth Company false
  • entity File Number 000-19125
  • entity Filer Category Large Accelerated Filer
  • entity Incorporation State Country Code DE
  • entity Interactive Data Current Yes
  • entity Name IONIS PHARMACEUTICALS INC
  • entity Registrant Name Ionis Pharmaceuticals, Inc.
  • entity Shell Company false
  • entity Small Business false
  • entity Tax Identification Number 33-0336973
  • income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest --112,943,000
  • income Tax Expense Benefit 11,400,000
  • increase Decrease In Accounts Payable --10,295,000
  • increase Decrease In Contract With Customer Liability --13,037,000
  • increase Decrease In Inventories 167,000
  • increase Decrease In Other Operating Assets --5,312,000
  • interest Expense 1,608,000
  • interest Paid Net 89,000
  • inventory Net 22,200,000
  • irs Number 330,336,973
  • liabilities 2,398,651,000
  • liabilities And Stockholders Equity 2,885,221,000
  • liabilities Current 259,221,000
  • local Phone Number 931-9200
  • net Cash Provided By Used In Financing Activities 492,087,000
  • net Cash Provided By Used In Investing Activities --325,640,000
  • net Cash Provided By Used In Operating Activities --133,992,000
  • net Income Loss --124,323,000
  • operating Income Loss --114,148,000
  • operating Lease Liability Noncurrent 177,000,000
  • operating Lease Right Of Use Asset 179,148,000
  • other Assets Current 159,724,000
  • other Assets Noncurrent 78,296,000
  • other Liabilities Current 8,239,000
  • other Liabilities Noncurrent 7,487,000
  • other Nonoperating Income Expense 230,000
  • payments Related To Tax Withholding For Share Based Compensation 0
  • payments To Acquire Available For Sale Securities Debt 688,278,000
  • payments To Acquire Property Plant And Equipment 10,472,000
  • period End 1,680,220,800,000
  • period Start 1,672,531,200,000
  • property Plant And Equipment Net 85,158,000
  • report Link https://www.sec.gov/Archives/edgar/data/874015/000087401523000136/form10q_htm.xml
  • retained Earnings Accumulated Deficit --1,553,948,000
  • revenue From Contract With Customer Excluding Assessed Tax 130,524,000
  • selling General And Administrative Expense 45,516,000
  • share Based Compensation 26,948,000
  • stockholders Equity 486,570,000
  • trading Symbol IONS
  • update 1970-01-01
  • weighted Average Number Of Diluted Shares Outstanding 142,735,000
  • weighted Average Number Of Shares Outstanding Basic 142,735,000
  • id REPORTED_FINANCIALS
  • key IONS
  • subkey 10-Q
  • date 2023-05-03
  • updated 2023-05-04

Related News

Oklo Eyes $30 After 38% 2-Day Rally as $3.13B Cash Pile Offsets Aurora’s 2028–2029 Startup Slip

Oklo Eyes $30 After 38% 2-Day Rally as $3.13B Cash Pile Offsets Aurora’s 2028–2029 Startup Slip

Itai Smidt 09.11.26
Stocks OKLO SMR CEG NNE
AMD ($500.16) Erases Midterm Crash While Nvidia Falls 4% — $600 Target After Record $13.38B Quarter

AMD ($500.16) Erases Midterm Crash While Nvidia Falls 4% — $600 Target After Record $13.38B Quarter

Itai Smidt 09.11.26
Stocks AMD NVDA SMCI MU
S&P 500 Hits 7,517, Nasdaq Jumps 578 Points, Dow Climbs to 52,139 as NVDA Sheds $175B

S&P 500 Hits 7,517, Nasdaq Jumps 578 Points, Dow Climbs to 52,139 as NVDA Sheds $175B

Itai Smidt 09.11.26
Stocks Markets IONS NVDA AMD CEG
SCHD ETF Holds Up in the Sell-Off, but Texas Instruments, a 15.64% Healthcare Weight and 1.95% Dividend Growth Cap the Upside — $35

SCHD ETF Holds Up in the Sell-Off, but Texas Instruments, a 15.64% Healthcare Weight and 1.95% Dividend Growth Cap the Upside — $35

Itai Smidt 06.11.26
Stocks Markets PEP CVX QCOM KO
Jfrog Erases Thursday’s 13.57% AI Sell-Off as 124% Net Retention — $88–$110 Range Into February

Jfrog Erases Thursday’s 13.57% AI Sell-Off as 124% Net Retention — $88–$110 Range Into February

Itai Smidt 06.11.26
Stocks FROG PANW CHKP CRWV
Moderna Hits a $263.44 High After a $0.38 EPS Beat, but Guidance Implies Q4 Revenue Falls 14%–42% — $215–$280 Range Into Analyst Day

Moderna Hits a $263.44 High After a $0.38 EPS Beat, but Guidance Implies Q4 Revenue Falls 14%–42% — $215–$280 Range Into Analyst Day

Itai Smidt 06.11.26
Stocks MRNA NVO JNJ PFE
Trade Now
© Trading News. All Rights Reserved Since 2022